Home・Список акций・Guardant Health Inc

Guardant Health Inc

Открыт

СекторЗдравоохранение

166.33 -0.72

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

165.02

Макс.

171.56

Ключевые показатели
By Trading Economics
Доход	-8.1M -120M
Продажи	33M 335M
Прибыль на акцию	-0.89
Рентабельность продаж	-35.866
Сотрудники	2,490
EBITDA	-8.1M -109M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+13.7% upside

Дивиденды
By Acuity
Следующий отчет о доходах	28 окт. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	2B 21B
Предыдущая цена открытия	167.05
Предыдущая цена закрытия	166.33

Новостные настроения

By Acuity

50%

116 / 340 Рейтинг в Healthcare

Guardant Health Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

7 авг. 2026 г., 20:03 UTC

Guardant Health Inc shares are advancing amid strong momentum and high trading volume. Broader market gains coincide with a decline in Treasury yields.

6 авг. 2026 г., 19:36 UTC

Guardant Health Inc shares are lower today, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

3 авг. 2026 г., 19:56 UTC

News

Guardant Health shares are higher as Stifel and Canaccord maintain Buy ratings, raising price targets to $180 and $205, respectively.

31 июл. 2026 г., 19:51 UTC

News

Social Media

Guardant Health Inc shares are trading higher as analysts raise price targets following strong second-quarter results and an upward revision of full-year revenue guidance.

30 июл. 2026 г., 23:21 UTC

News

Social Media

Guardant Health reported second-quarter revenue of $335 million, raising 2026 guidance to $1.34 billion to $1.36 billion, boosting shares in after-market hours.

29 июл. 2026 г., 18:54 UTC

Macro Event

News

Guardant Health Inc shares are higher as investors anticipate Q2 earnings on Thursday, following last quarter's revenue of $301.7 million, up 48.3% year-over-year.

28 июл. 2026 г., 19:16 UTC

News

Guardant Health shares are lower despite a tribute video featuring Patrick Dempsey and RBC's note on potential coverage tailwinds for the company.

27 июл. 2026 г., 19:36 UTC

News

Guardant Health Inc shares are lower, continuing a five-day decline despite a 48% year-over-year revenue increase and strong performance in the Shield segment.

24 июл. 2026 г., 18:36 UTC

Guardant Health Inc shares are lower today, continuing a decline since Thursday's close and remaining below the 20-day moving average.

20 июл. 2026 г., 20:02 UTC

News

Guardant Health Inc shares are lower today, continuing a decline since Friday amid mixed U.S. market performance and ongoing geopolitical tensions impacting investor sentiment.

Сравнение c конкурентами

Изменение цены

Guardant Health Inc Прогноз

Целевая цена

By TipRanks

13.7% рост

Прогноз на 12 месяцев

Средняя 191.56 USD 13.7%

Максимум 215 USD

Минимум 125 USD

Основано на мнении 21 аналитиков Wall Street, спрогнозировавших целевые цены для Guardant Health Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

21 ratings

Покупка

Удержание

Продажа

Основано на мнении 21 аналитиков, присваивавших рейтинги акциям Guardant Health Inc – Данные за последние 3 месяца.

Настроения

By Acuity

116 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.